Becaplermin

Identification

Name
Becaplermin
Accession Number
DB00102 / 1B56C968OA
Groups
Regranex
Description

Becaplermin is produced via recombinant DNA generation by means of insertion of the gene for the B chain of platelet derived growth issue (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of about 25 KD and is a homodimer composed of same polypeptide chains which might be sure together by means of disulfide bonds.

Pharmacology

Pharmacodynamics

Used for the topical treatment of skin ulcers, Regranex has a biological activity similar to that of endogenous platelet-derived growth factor, which includes promoting the chemotactic recruitment and proliferation of cells involved in wound repair and enhancing the formation of granulation tissue.

Indication

For topical treatment of skin ulcers (from diabetes)

Action

Binds to the beta platelet-derived growth factor (PDGF) receptor, a tyrosine kinase receptor. PDGF is known to exist as a dimer, and activates its signaling pathway by a ligand induced receptor dimerization and autophosphorylation. PDGF receptors also contain many auto-phosphorylation sites, which serve to mediate binding of SH2 sites and subsequently signal corresponding pathways. There are five different isoforms of PDGF that activate through two different receptors (alpha and beta).